172
(2.97-fold), fasting glucose (13.46-fold), and BMI-adjusted fasting glucose (7.43-fold)
173
( Figure 3A , p<5.43e-04, < 0.10 after Bonferroni correction).
174
These analyses highlighted 13 T2D-associated variants overlapping islet caQTLs Table enumerating the 13 caQTLs linked to T2D-associated GWAS SNVs. Asterisks mark those loci that were tested for differential luciferase activity in panel E. (C) Average chromatin accessibility profiles at the ADCY5 locus (loss-of-function T2D caQTL). The inset boxplot shows the fraction of ATAC-seq reads containing the G allele in each of the heterozygous islet samples (n=5). (D) Average chromatin accessibility profiles at the IL20RA locus (gain-of-function T2D caQTL). The inset boxplot shows the fraction of ATAC-seq reads containing the C allele in each of the heterozygous islet samples (n=11). (E) Luciferase activity of 9 tested caQTLs with reference and alternate alleles (normalized to empty construct) **** and *** indicate p<0.0001 and p<0.001, respectively; two-sided Mann-Whitney test p-values are shown on boxplots. ns = not significant. Fraction of reads with 'C' allele 
Shubham_Fig3
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To validate a subset (n=9) of the islet caQTLs, we tested whether the human 195 caQTL alleles altered enhancer activity of the sequences overlapping these putative cis-
196
REs using luciferase reporter assays in MIN6 beta cells. Comparison of sequences 197 containing either the reference or alternate allele for each caQTL site (Table 4) 198 confirmed differential enhancer activity for 5 out of 9 loci ( Figure 3E ). For example, the 199 rs6937795 "A" allele in the IL20RA locus, which is associated with increased T2D
200 susceptibility and increased islet chromatin accessibility ( Figure 3D ), showed 2.5-fold 201 higher enhancer activity than the non-risk "C" allele ( Figures 3B, 3D, 3E ).
203

Chromatin accessibility changes in T2D versus ND islets 204
To uncover T2D associated changes in chromatin accessibility, we compared 205 chromatin accessibility maps from 5 ND and 5 T2D donors ( Figure 4A ). Out of 52,387
206 ATAC-seq peaks tested, 1882 differentially accessible peaks between T2D and ND 207 islets were identified (FDR 10%). Of these, 980 showed an increase and 902 showed a 208 decrease in accessibility with the T2D state, hereafter referred to as "opening" and "closing" peaks, respectively ( Figure 4B ). There was a remarkable difference in the 210 functional annotation of differential peaks, where closing peaks were mostly found at 211 enhancers (48%), and opening peaks were mainly at promoters (70%) ( Figure 4C ).
212 Figure 4D and 4E represents examples of closing and opening peaks respectively.
213
However, when differential peaks were categorized with respect to the presence 214 or absence of ATAC-seq peaks in normal and diabetic donors ( Fig S3E) , we found that 215 the majority of T2D-associated changes in chromatin accessibility were gradient in 216 nature, i.e., peaks do not completely appear/disappear in T2D islets, with a few 217 exceptions (<1%) (Supplementary Figure S3E) . Additionally, we note that a subset of the 218 1882 differentially accessible peaks (42 opening peaks, 51 closing peaks) overlapped 219 caQTLs (Supplementary Figure S3F ), suggesting that these T2D associated 220 accessibility changes are driven by genetic factors.
221
The differential peaks were annotated to the closest active genes in islets 222 (Methods), resulting in 898 genes associated with opening and 665 genes associated 223 with closing peaks ( Supplemental Table S5 ). Differential gene expression analyses Figure 4F ). Opening and closing peaks were enriched 229 in different TF motifs ( Figure 4G ). Interestingly, TFs that regulate stress responses such 230 as ATF3, AP-1 were enriched in closing peaks.
Discussion
233
Using ATAC-seq, we profiled the chromatin accessibility of human islets from 19 ChromHMM annotations for ATAC-seq peaks (n=52387), differential peaks (n=1882), opening (n=980) and closing (n=902) peaks. Note that closing peaks are primarily at enhancer elements, whereas opening peaks are at promoter peaks. (D) Chromatin accessibility levels for an example loci around the BHLHE41 gene that contains a closing peak (marked in gray bar). (E) Chromatin accessibility levels for an example loci in the TIMM23B gene that contains an opening peak. (F) Gene expression changes (measured in log fold change) for promoter peaks that are closing or opening in T2D islets. Note that genes with opening peaks have positive fold change, i.e., increased expression with T2D, whereas genes with closing peaks have negative fold change, i.e., decreased expression in T2D (p=0.038; Mann-Whitney test). (G) TF motif enrichment p-values for opening and closing peaks.
use.
These caQTLs were enriched in islet-specific enhancers and TF motifs.
237
Importantly, a subset of these was significantly and specifically enriched for T2D and 238 fasting glucose GWAS index or linked (r 2 >0.8) sequence variants. Comparison of ATAC-239 seq profiles from T2D and ND individuals revealed quantitative changes in chromatin 240 accessibility at 1882 putative islet cis-REs. Together, these data and analyses 241 contribute significantly to (1) enumerating the genetic variants that alter islet cis-RE use;
242
(2) delineating putative functional variants among the T2D-and islet dysfunction- RNA-seq and chromatin-based assays that may contribute to these modest overlaps.
261
For example, features reflected in RNA-seq data such as mRNA stability, 
281
In this study, we identified SNVs in 13 T2D-associated loci that alter chromatin 282 accessibility. These include four loci (ZMIZ1, MTNR1B, RNF6, and ADCY5) in which the 283 same or linked (r2>0.8) genetic variant has been identified as an islet eQTL. Importantly,
284
the caQTL and eQTL studies identified a consistent direction-of-effect (e.g., gain-or 285 loss-of-function) for the risk allele in each of these loci. T2D risk alleles in 5/13 loci were 286 associated with reduced chromatin accessibility. For the remaining loci, the risk alleles 287 were associated with increased chromatin accessibility, representing potential gain-of-function variants. Unfortunately, sequence motif analysis of these caQTL variants did not 289 reveal obvious trans-factors that may be responsible for these accessibility differences 290 or whose binding is affected by this sequence variant. This could be due in part to 291 incomplete information on position weight matrices for TFs, including ARX, which is an 292 islet alpha cell transcription factor. Together, these data and analyses have identified 293 novel SNV effects on islet cis-REs, including their direction-of-effect, that can be further 294 dissected in a site-specific and hypothesis-driven manner.
295
By comparing ATAC-seq profiles from T2D and ND donors, we identified 980 and 296 902 regulatory elements that exhibit quantitative T2D-associated increases or decreases 297 in chromatin accessibility, respectively. These data suggest that T2D state by itself may 298 not lead to widespread changes in chromatin accessibility. However, we acknowledge 299 that T2D-associated epigenomic changes may be masked by multiple factors, including: 
303
Moving forward, studies that account for these potential confounders in larger,
304
genetically-stratified islet cohorts will be necessary to further confirm these T2D- 
312
(ProdoLabs) and kept in a T-150 non-tissue culture treated flask (VWR) for recovery at 313 37 C and 5% CO 2 overnight. ATAC-seq and RNA-seq were performed the following day 
328
Chromatin accessibility analysis (ATAC-seq):
329
Human islet ATAC-seq libraries were prepared as described ).
330
Approximately 50-100 islet equivalents (50,000-100,000 cells) per sample were 331 transposed in triplicate. Libraries were sequenced on an Illumina NextSeq500 (see 332 Table   473 enumerating the 9 caQTLs that were tested for luciferase activity. Note that higher 474 accessibility is associated with higher enhancer activity for all the 5 caQTLs displaying 
489
490 Supplementary Table Legends 491 Table S1 . Meta data associated with the 19 islets.
492 Table S2 . ATAC-seq quality control metrics for the 19 islets.
493 Table S3 . RNA-seq quality control metrics for the 19 islets.
494 Table S4 . Constructs for Luciferase Assay 
